摘要
研究基质金属蛋白酶 9(matrixmetalloproteinase 9,MMP9)及其抑制剂 (tissueinhibitorofmetalloproteinase 1,TIMP1)和血管内皮生长因子 (vascularendothelialgrowthfactor,VEGF)在子宫内膜异位症 (endometriosis,EM)患者的在位内膜中的表达。采用免疫组化SP法分别检测 4 5例EM(研究组 )在位内膜及 32例子宫肌瘤 (对照组 )的在位内膜中MMP9、TIMP1及VEGF的表达。MMP9、TIMP1、MMP9 TIMP1和VEGF在研究组和对照组的表达分别为 0 336 ,0 2 76 ;0 2 5 3,0 2 6 7和 1 2 93,1 0 34;0 372 ,0 2 88。其中MMP9、MMP9 TIMP1和VEGF在研究组中的表达显著高于对照组内膜 (P <0 0 1)。EM患者的在位内膜中MMP9、VEGF高表达可能是EM发生发展的重要原因。诊刮筛选出高MMP9、VEGF表达的在位内膜可望成为预测和诊断EM的方法之一。
To study the expression of MMP9 , TIMP1 and VEGF in eutopic endometrium in patients with endometriosis. The expressions of MMP9,TIMP1,MMP9/TIMP1,VEGF in eutopic endometrium were detected by immunohistochemistry SP method. Image dissector is used to determine that corresponding density. The expressions of MMP9,TIMP1,MMP9/TIMP1 and VEGF in eutopic and in the control group endometrium are 0.336,0.276;0.253,0.267 and 1.293,1.034;0.372,0.288 respectively. The expressions of MMP9,MMP9/TIMP1,VEGF are higher in eutopic endometrium than those of control group (P<0.01 or P<0.05). The high expressions of MMP9 and VEGF in eutopic endometrium in patients with EM may be related to the pathogenesis of EM. The expressions of high MMP9 and VEGF in eutopic endometrium are expected to create a diagnostic methods of EM.
出处
《基础医学与临床》
CSCD
北大核心
2004年第4期418-421,共4页
Basic and Clinical Medicine
基金
厦门科研基金 (2 0 0 1V4 )
